NASDAQ:CDNA CareDx Q3 2025 Earnings Report $14.97 +0.27 (+1.84%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$14.92 -0.06 (-0.37%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CareDx EPS ResultsActual EPSN/AConsensus EPS $0.13Beat/MissN/AOne Year Ago EPSN/ACareDx Revenue ResultsActual RevenueN/AExpected Revenue$95.25 millionBeat/MissN/AYoY Revenue GrowthN/ACareDx Announcement DetailsQuarterQ3 2025Date11/4/2025TimeAfter Market ClosesConference Call DateTuesday, November 4, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile CareDx Earnings HeadlinesCareDx Appoints Suresh Gunasekaran as New DirectorOctober 24 at 4:51 PM | tipranks.comCareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart ...October 24 at 2:12 AM | finance.yahoo.comOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology. | Banyan Hill Publishing (Ad)CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart FailureOctober 23 at 4:05 PM | businesswire.comCareDx Announces Appointment of Suresh Gunasekaran to Board of DirectorsOctober 22 at 7:11 PM | finance.yahoo.comCareDx to Report Third Quarter 2025 Financial Results on November 4, 2025October 21, 2025 | businesswire.comSee More CareDx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CareDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CareDx and other key companies, straight to your email. Email Address About CareDxCareDx (NASDAQ:CDNA) (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey. The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring. CareDx also offers a range of clinical laboratory services and companion diagnostic solutions that support patient management in lung and liver transplantation. Headquartered in Brisbane, California, CareDx serves transplant centers across the United States, Europe and select international markets. The company operates a network of CLIA‐certified laboratories and collaborates with academic institutions and transplant centers to advance research in immunological monitoring and personalized patient care. CareDx was established through the integration of Viracor-IBT and Transplant Genomics in 2018, building on more than a decade of molecular diagnostic expertise. The company’s leadership team comprises seasoned professionals with backgrounds in biotechnology, laboratory operations and clinical research, all dedicated to improving outcomes for transplant recipients worldwide.View CareDx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
